Patent RU-2632897-C2 (RU)
Title: Substituted derivatives of 3-heteroaroylaminopropionic acid and their application as drugs
Inventor: RUF SVEN
IPC: C07D413/06
Filed: 2012-01-26
Granted: 2017-10-11
Abstract: FIELD: pharmacology. 
     SUBSTANCE: invention relates to a compound of formula I 
     
       
     
     in any of its stereoisomeric forms or a physiologically acceptable salt thereof, wherein A is selected from the group consisting of C(R 1 ) and N; D is selected from the group consisting of C(R 2 ) and N; E is selected from the group consisting of C(R 3 ) and N; L is selected from the group consisting of C(R 4 ); where at least one and not more than two of A, D, E or L is N; G is selected from the group consisting of R 71 -O-C(O)-;R 1  is selected from the group consisting of hydrogen, halogen; R 2  is selected from the group consisting of hydrogen, halogen, (C 1 -C 7 )-alkyl, Het 2  and Ar-C s H 2s -, where s is 0; R 3  is selected from the group consisting of hydrogen, Het 2 , R 11 -O-; R 4  and R 10  are selected from the group consisting of hydrogen, halogen; provided that one of the R 2 , R 3  is a cyclic substituent; R 11  is selected from the group consisting of hydrogen, R 14 ; R 12  and R 13  are hydrogen; R 14  is (C 1 -C 10 )-alkyl optionally substituted by one substituent, which is an oxo group; R 30  is selected from the group consisting of R 31 , R 32 -C u H 2u -, where u is 0; R 31  is (C 1 -C 10 )-alkyl; R 32  is phenyl, wherein phenyl is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl-O-, CF 3 -; R 40 , R 50 , R 60  and R 71  are hydrogen; Ar, independently of other Ar groups, is selected from the group consisting of phenyl and aromatic 5-membered or 6-membered monocyclic heterocycle which includes one, two or three identical or different ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and is bonded through the carbon atom of the ring, wherein phenyl and heterocycle are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C 1 -C 6 )-alkyl, HO-(C 1 -C 6 )-alkyl, Het 4 , (C 1 -C 6 )-alkyl-O-, -CF 3 , -CO-(C 1 -C 6 )-alkyl, -CO-NR 12 R 13  and NC-; and wherein phenyl can be substituted with -CH=CH-CH=CH-, -O-CH 2 -O-, -O-CH 2 -CH 2 -O-, -O-CF 2 -O- or -N((C 1 -C 3 )-alkyl) -CH=CH-; Het 2  is a saturated 5-membered - 6-membered monocyclic heterocycle that includes a nitrogen atom in the ring through which Het 2  is attached and optionally one other ring heteroatom selected from the group consisting of nitrogen and oxygen; Het 4 , regardless of other Het 4  groups, is a saturated or unsaturated 4-membered to 5-membered monocyclic heterocycle that includes one to three ring heteroatoms selected from the group consisting of nitrogen and oxygen which is optionally substituted by one or more identical or different substituents selected from the group consisting of (C 1 -C 4 )-alkyl, HO-, (C 1 -C 4 )-alkyl-O-. Compounds of formula are obtained by the reaction of a compound of formula II   with a compound of formula III, where the A, D, E, L, G, R 10 , R 30 , R 40 , R 50  and R 60  groups such as defined above for compounds of formula I, and additional functional groups may be present in protected form or in the form of a precursor group, and group J in the compound of formula II is HO-, (C 1 -C 4 )alkyl-O- or halogen. 
     EFFECT: substituted derivatives of 3-heteroaroylaminopropionic acid for application as a pharmaceutical agent for catheptase protease A inhibition. 
     10 cl, 1 tbl, 620 ex